Skip to main content
Top
Published in: Rheumatology International 3/2013

01-03-2013 | Original Article

Excess weight and associated risk factors in patients with systemic lupus erythematosus

Authors: Fabiana de Miranda Moura dos Santos, Mariane Curado Borges, Rosa Weiss Telles, Maria Isabel T. D. Correia, Cristina Costa Duarte Lanna

Published in: Rheumatology International | Issue 3/2013

Login to get access

Abstract

The objective of this study is to determine the socio-demographic, clinical and laboratory characteristics of outpatients with SLE who present with excess weight as well as to assess the immunosuppressive therapy used. One hundred and seventy women with SLE were evaluated consecutively in a transversal study. The relationship between excess weight and the patients’ characteristics was evaluated using univariate and multivariate Poisson regression analysis. Of the 170 patients evaluated, 109 presented with excess weight, two were malnourished and 59 were classified as eutrophic. Age and disease duration of those with excess weight were 42.4 ± 8.7 and 10.4 ± 6.2 years, respectively. Risk factors associated with excess weight were the following: age ≥40 years, <8 years of education, lack of occupation, damage index ≥1, systemic high blood pressure, diabetes mellitus and triglycerides ≥150 mg/dL levels. The use of antimalarial therapy and steroids was associated with a lower frequency of excess weight. Age ≥40 years and the non-usage of methotrexate were the variables independently associated with excess weight in the multivariate analysis. Patients with SLE who have excess weight present distinct clinical-laboratory findings, socio-demographic characteristics and treatment options when compared to normal weight patients. Prospective studies should assess whether these characteristics will interfere with the outcome or prognosis of lupus.
Literature
2.
go back to reference Oeser A, Chung CP, Asanuma Y, Avalos I, Stein M (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52(11):3651–3659PubMedCrossRef Oeser A, Chung CP, Asanuma Y, Avalos I, Stein M (2005) Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum 52(11):3651–3659PubMedCrossRef
3.
go back to reference Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, LUMINA Study Group et al (2007) The impact of increased body mass index on systemic lupus erythematosus. J Clin Rheumatol 13(3):128–133PubMedCrossRef Chaiamnuay S, Bertoli AM, Fernández M, Apte M, Vilá LM, LUMINA Study Group et al (2007) The impact of increased body mass index on systemic lupus erythematosus. J Clin Rheumatol 13(3):128–133PubMedCrossRef
4.
go back to reference Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175PubMedCrossRef Petri M (2000) Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 9:170–175PubMedCrossRef
5.
go back to reference Lee S–S, Singh S, Magder LS, Petri M (2008) Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 17:114–123PubMedCrossRef Lee S–S, Singh S, Magder LS, Petri M (2008) Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus. Lupus 17:114–123PubMedCrossRef
6.
go back to reference Bultink IEM (2010) Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. Arthritis Res Ther 12(107–108):107PubMedCrossRef Bultink IEM (2010) Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. Arthritis Res Ther 12(107–108):107PubMedCrossRef
7.
go back to reference Tan EM, Cohen AS, Fries JF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982(25):1271–1277CrossRef Tan EM, Cohen AS, Fries JF (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982(25):1271–1277CrossRef
8.
go back to reference Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef Hochberg MC (1997) Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725PubMedCrossRef
9.
go back to reference Onis M, Habicth JP (1996) Anthropometric reference data for international use: recommendations from a world health organization expert committee health organization. Am J Clin Nutr 64:650–658PubMed Onis M, Habicth JP (1996) Anthropometric reference data for international use: recommendations from a world health organization expert committee health organization. Am J Clin Nutr 64:650–658PubMed
10.
go back to reference Luiz RA, Magnanimi MMF (2004) Size of samples in epidemiological investigations In: Medronho R. Epidemiologia. 2a ed. São Paulo: Atheneu. Cap.10, p 415–427 Luiz RA, Magnanimi MMF (2004) Size of samples in epidemiological investigations In: Medronho R. Epidemiologia. 2a ed. São Paulo: Atheneu. Cap.10, p 415–427
11.
go back to reference V Brazilian Guidelines on Hypertension. Arq Bras Cardiol 2007;89(3):e24–e79 V Brazilian Guidelines on Hypertension. Arq Bras Cardiol 2007;89(3):e24–e79
12.
go back to reference American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 27:S5–S10CrossRef American Diabetes Association (2004) Diagnosis and classification of diabetes mellitus. Diabetes Care 27:S5–S10CrossRef
13.
go back to reference Lawrence NM (2009) Primary ovarian insufficiency. N Engl J Med 360(6):606–614CrossRef Lawrence NM (2009) Primary ovarian insufficiency. N Engl J Med 360(6):606–614CrossRef
14.
go back to reference Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29:288–291PubMed
15.
go back to reference Gladman DD, Ginzler EM, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef Gladman DD, Ginzler EM, Goldsmith C, Fortin P, Liang M, Urowitz M et al (1996) The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369PubMedCrossRef
16.
go back to reference Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395PubMedCrossRef Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE et al (2003) International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 35:1381–1395PubMedCrossRef
17.
go back to reference Matsudo SM, Araújo T, Matsudo VR, Andrade D, Andrade E, Oliveira LC et al (2001) International physical activity questionnaire (IPAQ): reproducibility and validity study in Brazil. Rev Bras Física Saúde 6:5–18 Matsudo SM, Araújo T, Matsudo VR, Andrade D, Andrade E, Oliveira LC et al (2001) International physical activity questionnaire (IPAQ): reproducibility and validity study in Brazil. Rev Bras Física Saúde 6:5–18
19.
go back to reference Bernatsky S, Biovin JF, Josefh L, Pierre YST, Moore A, Rajan R et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issue, and obesity. J Rheumatol 29:2551–2554PubMed Bernatsky S, Biovin JF, Josefh L, Pierre YST, Moore A, Rajan R et al (2002) Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issue, and obesity. J Rheumatol 29:2551–2554PubMed
20.
21.
go back to reference Telles RW, Lanna CCD, Ferreira GA, Carvalho MA, Ribeiro AL (2007) Frequency of atherosclerotic cardiovascular disease and its risk factors in patients with systemic lupus erythematosus. Rev Bras Reumatol 47(3):165–172CrossRef Telles RW, Lanna CCD, Ferreira GA, Carvalho MA, Ribeiro AL (2007) Frequency of atherosclerotic cardiovascular disease and its risk factors in patients with systemic lupus erythematosus. Rev Bras Reumatol 47(3):165–172CrossRef
22.
go back to reference Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu CG, Gao X et al (2009) Regulatory role of G protein coupled estrogen receptor for vascular function and obesity. Circ Res 104:288–291PubMedCrossRef Haas E, Bhattacharya I, Brailoiu E, Damjanovic M, Brailoiu CG, Gao X et al (2009) Regulatory role of G protein coupled estrogen receptor for vascular function and obesity. Circ Res 104:288–291PubMedCrossRef
23.
go back to reference Williamson DF, Kahn HS, Remington PL, Anda RF (1990) The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 150:665–672PubMedCrossRef Williamson DF, Kahn HS, Remington PL, Anda RF (1990) The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 150:665–672PubMedCrossRef
24.
go back to reference Jeffey RW, French SA (1996) Socioeconomic status and weight control practices among 20- to 45-year-old women. Am J Public Health 86(7):1005–1010CrossRef Jeffey RW, French SA (1996) Socioeconomic status and weight control practices among 20- to 45-year-old women. Am J Public Health 86(7):1005–1010CrossRef
25.
go back to reference Alarcón GS, McGwin GJr, Bastian HM, Roseman J, Lisse J, Fessler BJ et al (2001) for the Lumina study group Systemic Lupus Erythematosus in Three Ethnic Groups. VIII. Predictors of Early Mortality in the LUMINA Cohort. Arthritis Rheum 45(2):191–202 Alarcón GS, McGwin GJr, Bastian HM, Roseman J, Lisse J, Fessler BJ et al (2001) for the Lumina study group Systemic Lupus Erythematosus in Three Ethnic Groups. VIII. Predictors of Early Mortality in the LUMINA Cohort. Arthritis Rheum 45(2):191–202
26.
go back to reference Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J et al (2008) Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 17:849–859PubMedCrossRef Sabio JM, Zamora-Pasadas M, Jiménez-Jáimez J, Albadalejo F, Vargas-Hitos J et al (2008) Metabolic syndrome in patients with systemic lupus erythematosus from Southern Spain. Lupus 17:849–859PubMedCrossRef
27.
go back to reference Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R et al (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18:1019–1025PubMedCrossRef Bellomio V, Spindler A, Lucero E, Berman A, Sueldo R et al (2009) Metabolic syndrome in Argentinean patients with systemic lupus erythematosus. Lupus 18:1019–1025PubMedCrossRef
28.
go back to reference Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRef Petri M, Perez-Gutthann S, Spence D, Hochberg MC (1992) Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 93:513–519PubMedCrossRef
29.
go back to reference Cardoso CRL, Signorelli F, Papi JA, Salles GF (2008) Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Reumatol Int 28:323–327CrossRef Cardoso CRL, Signorelli F, Papi JA, Salles GF (2008) Prevalence and factors associated with dyslipoproteinemias in Brazilian systemic lupus erythematosus patients. Reumatol Int 28:323–327CrossRef
30.
go back to reference Petri M (1996) Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5:S16–S22PubMedCrossRef Petri M (1996) Hydroxychloroquine used in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5:S16–S22PubMedCrossRef
31.
go back to reference Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780–785PubMed Borba EF, Bonfa E (2001) Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 28:780–785PubMed
32.
go back to reference Fessler BJ, Alarcón G, McGwin Jr G, LUMINA Study Group et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473–1480 Fessler BJ, Alarcón G, McGwin Jr G, LUMINA Study Group et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52:1473–1480
33.
go back to reference Irastorza RG, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Berrriota MA et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583CrossRef Irastorza RG, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Berrriota MA et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583CrossRef
34.
go back to reference Fortin PR, Abrahamowic M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(13):1796–1804PubMedCrossRef Fortin PR, Abrahamowic M, Ferland D, Lacaille D, Smith CD, Zummer M (2008) Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 59(13):1796–1804PubMedCrossRef
35.
36.
go back to reference Sánchez Y, Carvallo A (2004) Methotrexate use in patients with systemic lupus erythematosus. Rev Méd Chile 132:195–201PubMed Sánchez Y, Carvallo A (2004) Methotrexate use in patients with systemic lupus erythematosus. Rev Méd Chile 132:195–201PubMed
37.
go back to reference Ogden CL, Carroll M, Curtin LR, McDowell MA, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295:1549–1555PubMedCrossRef Ogden CL, Carroll M, Curtin LR, McDowell MA, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295:1549–1555PubMedCrossRef
38.
go back to reference Kunitoshi I, Yoshiharu I, Kozen K, Taku I, Chiho I, Shuichi T (2004) Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65:1870–1876CrossRef Kunitoshi I, Yoshiharu I, Kozen K, Taku I, Chiho I, Shuichi T (2004) Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 65:1870–1876CrossRef
39.
go back to reference Tench CM, McCarthy J, McCurdie I, White PD, Cruz DPD (2003) Fatigue is systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 42:1050–1054PubMedCrossRef Tench CM, McCarthy J, McCurdie I, White PD, Cruz DPD (2003) Fatigue is systemic lupus erythematosus: a randomized controlled trial of exercise. Rheumatology 42:1050–1054PubMedCrossRef
40.
go back to reference Carvalho MRP, Sato E, Tebexreni AS, Heidecher RTC, Schenkman S, Neto TLB (2005) Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 53:838–844PubMedCrossRef Carvalho MRP, Sato E, Tebexreni AS, Heidecher RTC, Schenkman S, Neto TLB (2005) Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity and quality of life in patients with systemic lupus erythematosus. Arthritis Rheum 53:838–844PubMedCrossRef
42.
go back to reference Tench C, Bentley D, Vleck V, Mccurdie I, White P, D’Cruz D (2002) Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 29:474–481PubMed Tench C, Bentley D, Vleck V, Mccurdie I, White P, D’Cruz D (2002) Aerobic fitness, fatigue, and physical disability in systemic lupus erythematosus. J Rheumatol 29:474–481PubMed
Metadata
Title
Excess weight and associated risk factors in patients with systemic lupus erythematosus
Authors
Fabiana de Miranda Moura dos Santos
Mariane Curado Borges
Rosa Weiss Telles
Maria Isabel T. D. Correia
Cristina Costa Duarte Lanna
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2402-8

Other articles of this Issue 3/2013

Rheumatology International 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.